SCHEMBL14488305

SCHEMBL14488305

CC(C)(C)OC(=O)N1CCC2(CC2)CC1(C)C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
EPHX2 P34913 1/20 0.33
GPR119 Q8TDV5 3/20 0.33
HDAC2 Q92769 2/20 0.32
HDAC1 Q13547 1/20 0.32
SCD5 Q86SK9 1/20 0.32
GRIN2B Q13224 1/20 0.32
GRIN2C Q14957 1/20 0.32
CTSK P43235 1/20 0.32
NR1H2 P55055 2/20 0.31
NR1H3 Q13133 1/20 0.31
CYP11B2 P19099 1/20 0.31
PREP P48147 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14486969 0.87 GPR119 (0.36) USP2SMN1; SMN2EPHX2GPR119HDAC2
SCHEMBL25330533 0.86 GRIN2B (0.33) USP2SMN1; SMN2GPR119SCD5GRIN2B
SCHEMBL25330541 0.86 GRIN2B (0.33) USP2SMN1; SMN2GPR119SCD5GRIN2B
SCHEMBL6078246 0.85 USP2 (0.40) USP2SMN1; SMN2EPHX2GPR119GRIN2B
SCHEMBL4249117 0.85 USP2 (0.40) USP2SMN1; SMN2EPHX2GPR119GRIN2B
SCHEMBL7227763 0.85 USP2 (0.40) USP2SMN1; SMN2EPHX2GPR119GRIN2B
SCHEMBL192363 0.80 GRIN2B (0.41) USP2SMN1; SMN2GPR119GRIN2BGRIN2C
SCHEMBL387543 0.80 GRIN2B (0.41) USP2SMN1; SMN2GPR119GRIN2BGRIN2C
SCHEMBL631031 0.80 GRIN2B (0.41) USP2SMN1; SMN2GPR119GRIN2BGRIN2C
SCHEMBL705581 0.78 GRIN2B (0.38) USP2SMN1; SMN2GPR119GRIN2BGRIN2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181279-B2 Cyclic amine derivatives as EP4 receptor antagonists ROTTAPHARM BIOTECH S.R.L. (IT) 2015-11-10 US disclosed
US-9181279-B2 Cyclic amine derivatives as EP4 receptor antagonists ROTTAPHARM BIOTECH S.R.L. (IT) 2015-11-10 US disclosed
US-9181279-B2 Cyclic amine derivatives as EP4 receptor antagonists ROTTAPHARM BIOTECH S.R.L. (IT) 2015-11-10 US disclosed
EP-2729445-B1 CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS Rottapharm Biotech Srl (IT) 2015-10-21 EP disclosed
US-20150087626-A1 CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ROTTAPHARM BIOTECH S.R.L. (IT) 2015-03-26 US disclosed
US-20150087626-A1 CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ROTTAPHARM BIOTECH S.R.L. (IT) 2015-03-26 US disclosed
US-20150087626-A1 CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ROTTAPHARM BIOTECH S.R.L. (IT) 2015-03-26 US disclosed
EP-2729445-A1 CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS Rottapharm S.p.A. (IT) 2014-05-14 EP disclosed
WO-2013004290-A1 CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ROTTAPHARM S.P.A. (IT) 2013-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087626-A1 CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS PTGER4, PTGER1, PTGER3 USP2 4438/4885SMN1; SMN2 4790/4885EPHX2 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.